Exosome hair therapy in London: what you're actually paying £1,500 for, and whether the evidence supports it

Every few years a new regenerative treatment sweeps through the London aesthetics market with a compelling mechanism, spectacular pricing, and a supporting evidence base that consists largely of enthusiasm. Exosomes are the current occupant of that slot. That does not mean they don't work. It means nobody yet knows how well they work, and you are being asked to fund the discovery process.

This is a deliberately sceptical review, written by someone who offers regenerative adjuncts in practice. Scepticism here is not hostility; it is the appropriate response to a treatment priced at a multiple of the alternatives with a fraction of their data.

What exosomes actually are

Cells communicate partly by releasing extracellular vesicles between roughly 30 and 150 nanometres across. These carry proteins, lipids and RNA species, and they alter gene expression in recipient cells. In hair biology, the interest is in exosomes derived from mesenchymal stem cells or dermal papilla cells, which in laboratory and animal models promote the transition into the growth phase and delay regression.

Preclinical results are genuinely encouraging. Mouse models show accelerated anagen entry, and in vitro work shows dermal papilla proliferation. The gap between an excited mouse follicle and a durable improvement in a 42-year-old's crown is, however, where most promising hair therapies have historically died.

The regulatory position in the UK

No exosome product holds an MHRA licence for treating hair loss. Products reach London clinics through aesthetic supply routes and are administered off-label or as unlicensed preparations. There is no requirement for the standardisation you would expect of a medicine: two clinics can both offer 'exosome therapy' using products with entirely different vesicle counts, source tissue and purity.

The practical consequence for patients is that reviews and results are not transferable between clinics. A good result at one London clinic tells you very little about the product being injected at another.

Comparing the alternatives on price and evidence

• Minoxidil: strong randomised evidence, £15–£30 per month. Should be in place before anything injectable.
• Finasteride or dutasteride: strong randomised evidence, £15–£60 per month. The only agents addressing the actual driver of pattern loss.
• Microneedling: several small randomised trials showing benefit combined with minoxidil, £60–£200 per session or minimal cost at home.
• PRP: multiple randomised trials with modest positive effect, £400–£900 per session.
• Exosomes: minimal controlled human evidence in androgenetic alopecia, £800–£2,500 per session.
• The ordering is the entire recommendation: exhaust the evidenced, cheap options before purchasing the unevidenced, expensive one.

If you're going to do it anyway

• Ask which product and supplier is used, and request the characterisation data sheet — particle count, source and purity.
• Ask how many sessions their protocol involves and what the total cost is before committing to the first.
• Insist on standardised baseline photography and trichoscopy, with a review at month six.
• Do not stop minoxidil or your DHT inhibitor to 'test' exosomes; you will lose more from stopping than you gain from adding.
• Be sceptical of combination pricing where exosomes are bundled with microneedling — the microneedling may be doing the work.
• Get the refund and non-response policy in writing.

The bottom line

Exosome therapy might turn out to be a valuable adjunct. The biology is coherent and the safety record so far is unremarkable in the good sense. But a treatment costing two to three times PRP, with a small fraction of PRP's published evidence, should be a late consideration for patients who have already optimised the basics and have money they are comfortable spending on an experiment.

If a London clinic proposes exosomes as your first treatment, before minoxidil, before DHT suppression, and before anyone has photographed your scalp — that is a commercial recommendation, not a clinical one.